Click here for your copy of The World Federation of Hemophilia Shared Decision-making Tool, Hemostatic Rebalancing Therapy.
We’ve posted several entries about rebalancing therapy…
While Hympavzi, Alhemo, and Fitusiran are now approved, a group from the University of Bern is developing yet another RNAi-based inhibitor that suppresses protein S production, thus reducing the coagulation control effects of the APC pathway. Click here for their open-access abstract. You may also wish to obtain this March, 2025 preprint from your library: Eladnani RP, Schaeper U, Diab R, et al. Enhancing hemostasis potency in hemophilia with a small interfering RNA targeting protein S. J Thromb Haemost. 2025: S1538-7836(25)00201-6. doi: 10.1016/j.jtha.2025.03.021. Epub ahead of print. PMID: 40154791.
No comments here.